Financials data is unavailable for this security.
View more
Year on year Zhejiang Cheng Yi Pharmaceutical Co Ltd had little change in net income (from 161.58m to 162.90m). Revenues were also little changed (from 654.97m to 671.63m.)
| Gross margin | 66.13% |
|---|---|
| Net profit margin | 22.60% |
| Operating margin | 25.29% |
| Return on assets | 9.07% |
|---|---|
| Return on equity | 13.91% |
| Return on investment | 11.17% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Cheng Yi Pharmaceutical Co Ltd increased its cash reserves by 37.41%, or 79.83m. The company earned 194.78m from its operations for a Cash Flow Margin of 29.00%. In addition the company used 59.60m on investing activities and also paid 55.38m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.80 |
|---|---|
| Tangible book value per share | 3.57 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.38 |
|---|---|
| Quick ratio | 1.01 |
| Total debt/total equity | 0.2506 |
|---|---|
| Total debt/total capital | 0.1998 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 12.00% while earnings per share excluding extraordinary items growth only marginally increased 0.81%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.66% |
|---|---|
| Div growth rate (5 year) | 12.84% |
| Payout ratio (TTM) | 39.43% |
| EPS growth(5 years) | 10.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -4.40 |
More ▼
